Special Issue "Systems Medicine and Personalised Health and Therapy – Special Focus on Cardio-Metabolic Diseases and Cancer"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: 31 March 2019

Special Issue Editors

Guest Editor
Dr. Sophie Visvikis-Siest

DR1 Inserm, Université de Lorraine, Inserm, IGE-PCV, Nancy, France
E-Mail
Guest Editor
Dr. Charity Nofziger

Chief Science Officer, PharmGenetix Gmbh Niederalm-Anif, Austria
E-Mail
Guest Editor
Dr. Maria G. Stathopoulou

Université de Lorraine, Inserm, IGE-PCV, Nancy, France
E-Mail

Special Issue Information

Dear Colleagues

The goal of this Special Issue is to gather together a collection of original research articles as well as reviews presented at the 9th Santorini Conference “Systems Medicine and Personalised Health and Therapy "The Odyssey from Hope to Practice". Special Focus on Cardio-Metabolic Diseases and Cancer”.

The aim of the conference is to answer the following questions:
  • How can the variability in the human genome, in expressed proteins and in circulatory metabolites be useful and how can they be used for:
  • Risk prediction: in particular for cardio-metabolic diseases and cancer
  • Environmental risk assessments: screening for the individual answers to nutrition, alcohol, tobacco, exercise and life habits
  • Pharmacogenomics: measuring individual responses to drugs, including interactions with endogenous compounds
  • Can genetic screening help identify the individuals at greatest risk of cardio-metabolic diseases and cancer?
  • What is the greatest clinical need with regard to diagnosis, prediction and patient stratification for these pathologies and how is/can this be addressed?
  • Does a genetic risk score identify the patients at highest risk and is its use justified in clinical practice?
  • What are the challenges of the current clinical trials?
  • What findings are there related to comorbidities with aging?
  • What is the impact of pharmacogenomics on the:
    • Delivery of more predictable responses to drug therapy?
    • Minimisation of the occurrence and severity of adverse drug reactions?
    • Implementation of more cost-effective clinical trials?
    • Drug discovery and the drug development process?
  • Do the existing diagnostic tools respond to the needs of pharmacogenomics?

Reduced publication fees will apply for attendees. You can contact the Editorial Office for further details at [email protected]

Dr. Sophie Visvikis-Siest
Dr. Maria G. Stathopoulou
Dr. Charity Nofziger
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Human genome variability
  • Environmental risk assessment
  • Pharmacogenomics 
  • Genetic screening
  • Diagnosis 
  • Patient stratification 
  • Genetic risk score 
  • Clinical trials 
  • Aging 
  • Drug discovery and development
  • Cardio-metabolic diseases
  • Cancer

Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Research

Jump to: Review, Other

Open AccessArticle Association of TLR4 Polymorphisms, Expression, and Vitamin D with Helicobacter pylori Infection
J. Pers. Med. 2019, 9(1), 2; https://doi.org/10.3390/jpm9010002
Received: 15 November 2018 / Revised: 21 December 2018 / Accepted: 3 January 2019 / Published: 11 January 2019
PDF Full-text (433 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Helicobacter pylori (H. pylori) infection is the strongest recognized risk factor for gastric adenocarcinoma. Since previous observations have shown that polymorphisms in innate immune system genes, as well as vitamin D (VitD) levels, could modify the risk of infection with Helicobacter [...] Read more.
Helicobacter pylori (H. pylori) infection is the strongest recognized risk factor for gastric adenocarcinoma. Since previous observations have shown that polymorphisms in innate immune system genes, as well as vitamin D (VitD) levels, could modify the risk of infection with Helicobacter pylori (H. pylori), we analyzed the relation between single nucleotide polymorphisms (SNPs) in TLRs (TLR1, TLR2, TLR4) CD14, RUNX3 and VitD levels with H. pylori infection. A case-control study on four hundred sixty Lebanese individuals was conducted. Eleven SNPs in total were genotyped and gene expression analysis using real-time PCR was performed in white blood cells of a subsample of eight individuals. A total of 49% of the participants were affected. Although no direct association was found between the SNPs and H. pylori infection, rs4986790G>A and rs4986791T>C in TLR4 were negatively associated with VitD levels (β = −0.371, p = 5 × 10−3 and β = −0.4, p = 2 × 10−3, respectively), which was negatively associated with H. pylori infection (OR = 0.01, p < 1 × 10−3). TLR4 expression was 3× lower in individuals with H. pylori compared with non-infected (p = 0.01). TLR4 polymorphisms, expression, and VitD could be implicated in H. pylori infection and further development of gastric adenocarcinoma. Full article
Figures

Figure 1

Review

Jump to: Research, Other

Open AccessReview Personalised Medicine: The Odyssey from Hope to Practice
J. Pers. Med. 2018, 8(4), 31; https://doi.org/10.3390/jpm8040031
Received: 4 September 2018 / Revised: 17 September 2018 / Accepted: 18 September 2018 / Published: 21 September 2018
Cited by 1 | PDF Full-text (4207 KB) | HTML Full-text | XML Full-text
Abstract
In this endeavour, inspired by the Odyssey, we aim to embark with the reader on a journey on a ship from Troy to Ithaca, coursing through the history of the momentous events and achievements that paved the way for personalised medicine. We will [...] Read more.
In this endeavour, inspired by the Odyssey, we aim to embark with the reader on a journey on a ship from Troy to Ithaca, coursing through the history of the momentous events and achievements that paved the way for personalised medicine. We will set sail amidst important genetic discoveries, beginning with the discovery of the first human genome, and voyage through the projects that contributed to the progress of pharmacogenomic studies. Concurrently, we will propose methods to overcome the obstacles that are slowing the potential full implementation of accumulated knowledge into everyday practice. This journey aims to reflect on the frontiers of current genetic knowledge and the practical use of this knowledge in preventive, diagnostic and pharmacogenomic approaches to directly impact the socio-economic aspects of public health. Full article
Figures

Figure 1

Other

Jump to: Research, Review

Open AccessConference Report The 9th Santorini Conference: Systems Medicine, Personalised Health and Therapy. “The Odyssey from Hope to Practice”, Santorini, Greece, 30 September–3 October 2018
J. Pers. Med. 2018, 8(4), 43; https://doi.org/10.3390/jpm8040043
Received: 3 December 2018 / Accepted: 5 December 2018 / Published: 12 December 2018
PDF Full-text (752 KB) | HTML Full-text | XML Full-text
Abstract
The 9th traditional biannual conference on Systems Medicine, Personalised Health & Therapy—“The Odyssey from Hope to Practice”, inspired by the Greek mythology, was a call to search for practical solutions in cardio-metabolic diseases and cancer, to resolve and overcome the obstacles in modern [...] Read more.
The 9th traditional biannual conference on Systems Medicine, Personalised Health & Therapy—“The Odyssey from Hope to Practice”, inspired by the Greek mythology, was a call to search for practical solutions in cardio-metabolic diseases and cancer, to resolve and overcome the obstacles in modern medicine by creating more interactions among disciplines, as well as between academic and industrial research, directed towards an effective ‘roadmap’ for personalised health and therapy. The 9th Santorini Conference, under the Presidency of Sofia Siest, the director of the INSERM U1122; IGE-PCV (www.u1122.inserm.fr), University of Lorraine, France, offered a rich and innovative scientific program. It gathered 34 worldwide distinguished speakers, who shared their passion for personalised medicine with 160 attendees in nine specific sessions on the following topics: First day: The Odyssey from hope to practice: Personalised medicine—landmarks and challenges Second day: Diseases to therapeutics—genotype to phenotype an “-OMICS” approach: focus on personalised therapy and precision medicine Third day: Gene-environment interactions and pharmacovigilance: a pharmacogenetics approach for deciphering disease “bench to clinic to reality” Fourth day: Pharmacogenomics to drug discovery: a big data approach and focus on clinical data and clinical practice. In this article we present the topics shared among the participants of the conference and we highlight the key messages. Full article
Figures

Figure 1

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top